目的：评价DC联合CIK治疗156例局部晚期或晚期胰腺癌的临床疗效。方法：回顾性分析2011年11月至2023年 12月在东部战区总医院肿瘤科进行自体DC联合CIK治疗的156例局部晚期或晚期胰腺癌患者的临床资料。统计患者治疗前后 血清肿瘤标志物、淋巴细胞亚群、细胞因子水平的变化、不良反应发生情况以及近期疗效、远期疗效。结果：156例胰腺癌患者中 有 92 例治疗前后均进行了影像学检查，结果显示 CR 0 例，PR 0 例，SD 42 例，PD 50 例，ORR 为 0%，DCR 为 45.65%。外周血 CA199水平在治疗前后无显著差异，但有19例患者治疗后下降超过20%。治疗前后患者外周血CD3+ 、CD4+ 、CD8+ 、CD56+ 、CD25+ 淋巴细胞亚群水平和CD4+ /CD8+ T细胞比值无统计学差异（P>0.05），治疗后患者外周血IL-2、IFN-γ的平均水平均显著高于治疗前 （P<0.05），TNF-α和IL-6无显著差异（P>0.05）。156例患者mOS为8.53个月，1年累积生存率为39%，2年累积生存率为 15%，3 年累积 生存率为15%，没有随访到5年的生存数据。治疗过程中未发生严重不良反应。结论：DC-CIK能使局部晚期和晚期胰腺癌患者 产生抗肿瘤免疫反应，取得一定的客观疗效并可能使患者生存期延长。

Objective: To evaluate the clinical efficacy of dendritic cells (DC) combined with cytokine-induced killer cells (CIK) in the treatment of locally advanced or advanced pancreatic cancer. Methods: A retrospective analysis was conducted on the clinical data of 156 patients with locally advanced or advanced pancreatic cancer who underwent autologous DC combined with CIK treatment in the Oncology Department of the Eastern Theater Command General Hospital from November 2011 to December 2023. Changes in serum tumor markers, lymphocyte subsets, cytokine levels, adverse reactions, short-term efficacy, and long-term efficacy before and after treatment were statistically analyzed. Results: Among the 156 pancreatic cancer patients, 92 underwent imaging examinations before and after treatment, with results showing no CR (complete remission), no PR (partial remission), 42 cases of SD (stable disease), and 50 cases of PD (progressive disease). The objective remission rate (ORR) was 0%, and the disease control rate (DCR) was 45.65%. There was no significant difference in peripheral blood CA199 levels before and after treatment, but 19 patients showed a reduction of more than 20% after treatment. No statistical differences were observed in CD3+ , CD4+ , CD8+ , CD56+ , CD25+ peripheral blood lymphocyte subsets levels and CD4+ /CD8+ T cell ratio before and after treatment (all P>0.05). However, the average levels of IL-2 and IFN-γ in peripheral blood of patients were significantly increased after treatment (all PP>0.05). The median overall survival (mOS) of the 156 patients was 8.53 months, with 1-year, 2-year, and 3-year cumulative survival rates of 39%, 15%, and 15%, respectively. No 5-year survival data were available for follow-up. No severe adverse reactions occurred during the treatment. Conclusion: DC-CIK therapy can induce anti-tumor immune responses in patients with locally advanced and advanced pancreatic cancer, achieving certain objective efficacy and potentially prolonging patient survival.

2022东部战区总医院院管课题（No. 22JCYYYB1）